Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03651128
Title Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Acronym KarMMa-3
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | SWE | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL


No variant requirements are available.